CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

022450Orig1s000

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review

13 OCTOBER 2009

NDA: **22-450/N000**

Drug Product Name
Proprietary: Acetavance
Non-proprietary: Acetaminophen

Review Number: 1

Dates of Submission(s) Covered by this Review

Letter	Stamp	Review Request	Assigned to Reviewer
13-MAY-2009	13-MAY-2009	21-MAY-2009	3-JUN-2009

Submission History (for amendments only) – NA

Applicant/Sponsor
Name: Cadence Pharmaceuticals
Address: 12481 High Bluff Drive, Suite 200
San Diego, CA 92130
Representative: Malcolm Lloyd-Smith
Telephone: (858) 436-1400

Name of Reviewer: Denise Miller

Conclusion: Approve

Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: Original submission

2. SUBMISSION PROVIDES FOR: The submission provides for the manufacture and (b) (4) sterilization of acetaminophen for injection.

3. MANUFACTURING SITE:
Baxter Healthcare Corporation
911 North Davis Ave.
Cleveland, MS 38732
FDA Registration Number: 1019003

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:

- Liquid for Injection, 100 mL vials containing 100 mL
- Intravenous
- 10 mg/mL

5. METHOD(S) OF STERILIZATION: (b) (4)

6. PHARMACOLOGICAL CATEGORY: Treatment of pain and fever

B. SUPPORTING/RELATED DOCUMENTS:
Baxter DMF 4681 *Production of Parenteral Injections in Glass Containers*

C. REMARKS:
Submission is in e-CTD format.
Review of Baxter DMF 4681 concluded that the DMF was adequate to support NDA 22-450/N000. See DMF review D4681_2009OCT02_A1.doc.

filename: N022450N000R1.doc

Executive Summary

I. Recommendations

A. Recommendation on Approvability – Recommend to approve from a quality microbiology standpoint.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable – N/A

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – The manufacture and (b) (4) sterilization of acetaminophen injection.

B. Brief Description of Microbiology Deficiencies - None

C. Assessment of Risk Due to Microbiology Deficiencies -NA

III. Administrative

A. Reviewer's Signature _____
Denise A. Miller, Microbiologist

B. Endorsement Block _____
Bryan S. Riley, Ph. D.

C. CC Block
N/A

5 Pages have been Withheld in Full as b4 (CCI/TS) Immediately Following this Page

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22450	ORIG-1	CADENCE PHARMACEUTICALS INC	ACETAMINOPHEN FOR INJECTION FOR IV USE

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DENISE A MILLER
10/13/2009

BRYAN S RILEY
10/13/2009
I concur.

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number: 22-450 **Applicant:** Cadence Pharmaceuticals **Letter Date:** 13-MAY-2009

Drug Name: Acetavance **NDA Type:** 505(b)(2) **Stamp Date:** 13-MAY-2009

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	√		e-CDT format
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	√		
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?	√		(b) (4) sterilization (b) (4) reference to DMF 4681
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		√	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?	√		PE= NA CC = reference to DMF 4681
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	√		
7	Has the applicant submitted the results of analytical method verification studies?	√		
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?	NA		
9	Is this NDA fileable? If not, then describe why.	√		

Additional Comments: This submission is for acetaminophen to be administered I.V. without admixture. Label states that the product must be used within 6 hours of releasing vacuum in the vial and administered as a 15 minute infusion; therefore there are no post reconstitution microbial issues.

Denise Miller, Microbiologist Date

Bryan S. Riley, Ph.D. Date

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Denise Miller
7/9/2009 09:23:27 AM
MICROBIOLOGIST

Bryan Riley
7/9/2009 09:26:36 AM
MICROBIOLOGIST
I concur.